These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1765 related articles for article (PubMed ID: 18318825)

  • 41. Molecular epidemiological study of hepatitis B virus infection in two different ethnic populations from the Solomon Islands.
    Utsumi T; Yano Y; Truong BX; Tanaka Y; Mizokami M; Seo Y; Kasuga M; Kawabata M; Hayashi Y
    J Med Virol; 2007 Mar; 79(3):229-35. PubMed ID: 17245721
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatitis B virus genotypes and precore/core-promoter mutations in Tunisian patients with chronic hepatitis B virus infection.
    Ayed K; Gorgi Y; Ayed-Jendoubi S; Aouadi H; Sfar I; Najjar T; Ben Abdallah T
    J Infect; 2007 Mar; 54(3):291-7. PubMed ID: 16911832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double point mutation in the core promoter region of hepatitis B virus (HBV) genotype C may be related to liver deterioration in patients with chronic HBV infection.
    Nakashima H; Furusyo N; Kubo N; Kashiwagi K; Etoh Y; Kashiwagi S; Hayashi J
    J Gastroenterol Hepatol; 2004 May; 19(5):541-50. PubMed ID: 15086598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular and serological characterization of hepatitis B virus genotype A and D infected blood donors in Poland.
    Grabarczyk P; Garmiri P; Liszewski G; Doucet D; Sulkowska E; Brojer E; Allain JP;
    J Viral Hepat; 2010 Jun; 17(6):444-52. PubMed ID: 19780948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis B virus genotypes and hepatitis B surface antigen mutations in family contacts of hepatitis B virus infected patients with occult hepatitis B virus infection.
    Kumar GT; Kazim SN; Kumar M; Hissar S; Chauhan R; Basir SF; Sarin SK
    J Gastroenterol Hepatol; 2009 Apr; 24(4):588-98. PubMed ID: 19207682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
    Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
    J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients.
    Tsai MC; Chen CH; Lee CM; Chen YT; Chien YS; Hung CH; Wang JH; Lu SN; Yen YH; Changchien CS; Hu TH
    J Hepatol; 2009 Feb; 50(2):281-8. PubMed ID: 19070392
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low frequency of mutations in the X gene, core promoter and precore region of hepatitis B virus infected Vietnamese.
    Song LH; Duy DN; Binh VQ; Luty AJ; Kremsner PG; Bock CT
    J Viral Hepat; 2005 Mar; 12(2):160-7. PubMed ID: 15720531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Variations in the core promoter/pre-core region in HBV genotype C in Japanese and Northern Vietnamese patients.
    Truong BX; Yano Y; Seo Y; Phuong TM; Tanaka Y; Kato H; Miki A; Utsumi T; Azuma T; Trach NK; Mizokami M; Hayashi Y; Kasuga M
    J Med Virol; 2007 Sep; 79(9):1293-304. PubMed ID: 17607788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan.
    Chen CH; Lee CM; Lu SN; Changchien CS; Eng HL; Huang CM; Wang JH; Hung CH; Hu TH
    J Clin Microbiol; 2005 Dec; 43(12):6000-6. PubMed ID: 16333089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Mutation of hepatitis B virus DNA pre-C region in patients with primary hepatocellular carcinoma in Guangxi].
    Fang Z; He B; Zhuang H; Ring L; Harrison TJ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2000 Mar; 34(2):83-5. PubMed ID: 11860905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
    Cho SW; Hahm KB; Kim JH
    Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong.
    Chan HL; Leung NW; Hussain M; Wong ML; Lok AS
    Hepatology; 2000 Mar; 31(3):763-8. PubMed ID: 10706570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pre-core/basal-core promoter and reverse transcriptase mutations in chronic HBV infected-patients.
    Xu L; Chen EQ; Lei J; Liu L; Zhou TY; Gao Z; Tang H
    Hepatogastroenterology; 2012; 59(113):212-5. PubMed ID: 22251541
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion.
    Yuen MF; Wong DK; Zheng BJ; Chan CC; Yuen JC; Wong BC; Lai CL
    J Viral Hepat; 2007 Apr; 14(4):269-75. PubMed ID: 17381719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma.
    Yuen MF; Sablon E; Yuan HJ; Wong DK; Hui CK; Wong BC; Chan AO; Lai CL
    Hepatology; 2003 Mar; 37(3):562-7. PubMed ID: 12601354
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study.
    Chen CH; Changchien CS; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN
    J Infect Dis; 2008 Dec; 198(11):1634-42. PubMed ID: 18939932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low HBV-DNA levels in end-stage renal disease patients with HBeAg-negative chronic hepatitis B.
    Moutinho RS; Perez RM; Medina-Pestana JO; Figueiredo MS; Koide S; Alberto FL; Silva AE; Ferraz ML
    J Med Virol; 2006 Oct; 78(10):1284-8. PubMed ID: 16927290
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.
    Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
    J Med Virol; 2003 Jul; 70(3):355-60. PubMed ID: 12766997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma.
    Chou YC; Yu MW; Wu CF; Yang SY; Lin CL; Liu CJ; Shih WL; Chen PJ; Liaw YF; Chen CJ
    Gut; 2008 Jan; 57(1):91-7. PubMed ID: 17502344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 89.